Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
Bhaskar ST, Patel VG, Porter DL, Schuster SJ, Nastoupil LJ, Perales MA, Tomas AA, Bishop MR, McGuirk JP, Maziarz RT, Chen AI, Bachanova V, Maakaron JE, Riedell PA, Oluwole OO. Bhaskar ST, et al. Among authors: riedell pa. Blood Adv. 2023 Sep 12;7(17):4765-4772. doi: 10.1182/bloodadvances.2022008937. Blood Adv. 2023. PMID: 36508286 Free PMC article.
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis.
Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek AE, Riedell PA, Awan F, Samples L, Shadman M, Hu M, Bachanova V, Wesson W, Ahmed N, Iqbal M, Kharfan-Dabaja MA, Scordo M, Johnson PC, Chen YB, Ito S, Hamadani M, Frigault M. Alsouqi A, et al. Among authors: riedell pa. Am J Hematol. 2024 Aug;99(8):1624-1627. doi: 10.1002/ajh.27354. Epub 2024 May 20. Am J Hematol. 2024. PMID: 38769663 No abstract available.
BsAbs before CD19 CAR-T: full speed ahead!
Riedell PA. Riedell PA. Blood. 2024 Jul 18;144(3):249-251. doi: 10.1182/blood.2024025048. Blood. 2024. PMID: 39023866 No abstract available.
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ, Perales MA, Maziarz RT, Brower J, Shah GL, Chen AI, Oluwole OO, Schuster SJ, Bishop MR, McGuirk JP, Riedell PA. Ahmed N, et al. Among authors: riedell pa. Blood Adv. 2024 Oct 22;8(20):5346-5354. doi: 10.1182/bloodadvances.2023012549. Blood Adv. 2024. PMID: 39042880 Free PMC article.
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Scordo M, Flynn JR, Gonen M, Devlin SM, Parascondola A, Tomas AA, Shouval R, Brower J, Porter DL, Schuster SJ, Bachanova V, Maakaron J, Maziarz RT, Chen AI, Nastoupil LJ, McGuirk JP, Oluwole OO, Ip A, Leslie LA, Bishop MR, Riedell PA, Perales MA. Scordo M, et al. Among authors: riedell pa. Blood Adv. 2023 Sep 26;7(18):5579-5585. doi: 10.1182/bloodadvances.2023010302. Blood Adv. 2023. PMID: 37522731 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 39112401
71 results